



Silere OneMedForum Press Release

**FOR IMMEDIATE RELEASE**

Contact: Michael F. Langhout, MBA; co-founder, CEO, President, Silere Medical Technology, Inc.

+1-425-269-3000

***Silere Medical Technology Presenting the TheraStim 6000™***

***OneMedForum 2010 Finance Conference***

***Sir Francis Drake Hotel, San Francisco, CA***

***January 12<sup>th</sup>, 2010, 2:10 PM***

**Engineered Suppression of Chronic Tinnitus™**

Kirkland, Washington., December 21<sup>st</sup>, 2009-Medical device startup Silere Medical Technology, Inc. announced today that it will be presenting its at the OneMedForum Finance Conference, being held concurrently with the JP Morgan Conference.

**Silere invites all Venture Capital and Strategic Investors to attend the presentation of the TheraStim 6000™, The First Implantable Electrical Neurostimulation System for the Therapeutic Treatment of Chronic Tinnitus.**

The implantable microelectronic design concept follows the exclusive licensing agreement covering three United States issued patents with the University of Iowa Research Foundation. The three Iowa patents, combined with other engineering patents in the Silere portfolio will enable Silere to design, fabricate, and bring to market its TheraStim 6000™ neurostimulation device.

Encouraging proof of concept in humans has already been achieved, said Michael Langhout, Co-Founder, CEO, and President. ***“We have successfully demonstrated suppression of tinnitus in human patients, 71% of whom reported suppression of tinnitus percept within minutes of application of Silere’s proprietary therapeutic signal strategy. Achieving our objective of conducting a double-blind placebo controlled clinical study demonstrating proof of efficacy will be overwhelmingly compelling”.***

An emerging private company, Silere Medical is developing an electrical neural prosthesis to further validate its existing human data. Regulatory strategy for the company includes clinical trials in European centers to obtain CE Mark, concurrent with feasibility and pivotal IDE studies in the United States.



This platform integrates world –class expertise in electric neural stimulation of the cochlea, clinical research, and microelectronic neurostimulation device design including digital signal processing, hermetic packaging, custom integrated circuits, intracochlear electrode design, and biocompatible feedthrough and leads. Silere plans to integrate this technology into the TheraStim 6000™.

***“We are convinced that our experienced team can produce an effective neural stimulation prosthetic device that once implanted first in humans, will be very exciting for neurotologists globally, who currently are unable to offer an effective solution to this large unmet clinical need”, said Mr. Langhout.***

#### ***About Silere Medical Technology***

***Based in Kirkland, Wa., Silere Medical designs, fabricates, and markets electrical neurostimulation devices treating disorders of the auditory processing system. The primary focus is chronic tinnitus, a condition which can be debilitating for millions of people worldwide. Silere’s technology platform was developed at University of Iowa by internationally recognized thought leaders in disorders of the auditory processing system, cochlear implants, and tinnitus research.***

***Silere Medical was co-founded by industry veterans, including [William ‘Van’ Harrison, Jay T. Rubinstein, MD, PdD, Michael Langhout, MBA, and Dorcas Kessler, MA.](#) It is funded by its founders, and currently seeking Series A investment partners.***